1. Home
  2. CAPR vs GROY Comparison

CAPR vs GROY Comparison

Compare CAPR & GROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • GROY
  • Stock Information
  • Founded
  • CAPR 2005
  • GROY 2020
  • Country
  • CAPR United States
  • GROY Canada
  • Employees
  • CAPR N/A
  • GROY N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • GROY
  • Sector
  • CAPR Health Care
  • GROY
  • Exchange
  • CAPR Nasdaq
  • GROY Nasdaq
  • Market Cap
  • CAPR 322.7M
  • GROY 322.2M
  • IPO Year
  • CAPR N/A
  • GROY 2021
  • Fundamental
  • Price
  • CAPR $8.44
  • GROY $2.58
  • Analyst Decision
  • CAPR Strong Buy
  • GROY Strong Buy
  • Analyst Count
  • CAPR 8
  • GROY 3
  • Target Price
  • CAPR $24.75
  • GROY $3.67
  • AVG Volume (30 Days)
  • CAPR 2.7M
  • GROY 1.4M
  • Earning Date
  • CAPR 08-06-2025
  • GROY 08-12-2025
  • Dividend Yield
  • CAPR N/A
  • GROY N/A
  • EPS Growth
  • CAPR N/A
  • GROY N/A
  • EPS
  • CAPR N/A
  • GROY N/A
  • Revenue
  • CAPR $17,363,588.00
  • GROY $10,347,000.00
  • Revenue This Year
  • CAPR $453.92
  • GROY $88.55
  • Revenue Next Year
  • CAPR N/A
  • GROY $52.87
  • P/E Ratio
  • CAPR N/A
  • GROY N/A
  • Revenue Growth
  • CAPR N/A
  • GROY 99.94
  • 52 Week Low
  • CAPR $3.52
  • GROY $1.16
  • 52 Week High
  • CAPR $23.40
  • GROY $2.75
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 38.63
  • GROY 68.50
  • Support Level
  • CAPR $6.26
  • GROY $2.48
  • Resistance Level
  • CAPR $7.28
  • GROY $2.75
  • Average True Range (ATR)
  • CAPR 0.69
  • GROY 0.10
  • MACD
  • CAPR -0.04
  • GROY 0.01
  • Stochastic Oscillator
  • CAPR 10.28
  • GROY 87.76

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About GROY Gold Royalty Corp.

Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.

Share on Social Networks: